General form of registration statement for all companies including face-amount certificate companies

COMMITMENTS AND CONTINGENCIES (Details Narrative)

v3.22.1
COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Loss Contingencies [Line Items]    
Stock Issued During Period, Shares, New Issues 1,167,423 434,808
Research and Development Expense $ 647,302 $ 362,456
Chairman And CEO [Member]    
Loss Contingencies [Line Items]    
Defined Contribution Plan, Nature and Effect of Change, Description The employment agreements, as amended, for the Company’s Executive Chairman and CEO each contain a transaction bonus in the instance any of the Company’s assets are sold or sublicensed or if the Company or its subsidiary is acquired, equal to 1.75% of the consideration received by the Company. The employment agreement, as amended, for the Company’s General Counsel contains a similar transaction bonus equal to 0.5% of consideration received by the Company  
Employment Agreements [Member]    
Loss Contingencies [Line Items]    
Accrued Salaries, Current $ 83,731  
License Agreement [Member] | QSAM Therapeutics Inc [Member]    
Loss Contingencies [Line Items]    
Other Expenses $ 15,101 97,999
Royalty percentage 4.50%  
[custom:SublicensePercentage] 5.00%  
Consulting fee $ 8,500  
Payment for license fees   $ 60,000
License Agreement [Member] | QSAM Therapeutics Inc [Member] | Upon Commercialization [Member]    
Loss Contingencies [Line Items]    
Other Expenses $ 2,000,000  
Stock Issued During Period, Shares, New Issues 12,500  
License Agreement [Member] | QSAM Therapeutics Inc [Member] | Maximum [Member]    
Loss Contingencies [Line Items]    
Other Expenses $ 410,000